Exosome Dx Switches CEOs, Taps Ex-GnuBio Exec For Top Seat

Xconomy Boston — 

Cambridge, MA-based Exosome Diagnostics has named John Boyce its new CEO, taking over for Tom McLain. Boyce previously was the CEO of GnuBio, a DNA sequencing company that was sold to Bio-Rad for $110 million last year. Exosome, which is developing so-called liquid biopsies for prostate and lung cancer, is clearly thinking of a similar step—chairman Kapil Dhingra, in a statement, touted Boyce’s track record of “starting and growing companies to the IPO or acquisition stage.” Boyce is Exosome’s third CEO since its 2011 inception: McLain stepped in for founding CEO James McCullough in August 2014. Exosome said that McLain, meanwhile, will continue on with the company, but didn’t specify his role going forward.